Popular terms

G Proteins topics
G Proteins
Antibodies
Immunoglobulin
Metalloprotein
Chemotherapeutic Agent
Kinase Inhibitor
Tetrapeptide
Apoptosis Protein
Topoisomerase
Peptidomimetic
Fractionation
Medical Treatment
Chromatograph
Encapsulation
Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

G Proteins patents



      

This page is updated frequently with new G Proteins-related patent applications.




Date/App# patent app List of recent G Proteins-related patents
05/12/16
20160132634 
 Computer-implemented methods of determining protein viscosity patent thumbnailComputer-implemented methods of determining protein viscosity
The invention provides computer-implemented methods for screening proteins such as antibodies based on viscosity properties. The methods involve making a spatial charge map (scm) of the three-dimensional structure of the antibody or protein and determine a scm score depending on a condition such as e.g.
Novartis Pharma Ag


05/12/16
20160130568 
 Thermophilic and thermoacidophilic glycosylation genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods patent thumbnailThermophilic and thermoacidophilic glycosylation genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods
Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods for glycosylating and/or post-translationally modifying proteins using isolated and/or purified polypeptides and nucleic acid sequences from alicyclobacillus acidocaldarius..
Battelle Energy Alliance, Llc.


05/12/16
20160130332 
 Antibodies to human signal peptide-containing proteins patent thumbnailAntibodies to human signal peptide-containing proteins
The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation


05/12/16
20160130327 
 Cmv neutralizing antigen binding proteins patent thumbnailCmv neutralizing antigen binding proteins
The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (cmv). Also encompassed by the invention are antigen binding proteins that have been humanized.
Board Of Regents Of The University Of Texas System


05/05/16
20160123956 
 Modified membrane spanning proteins and methods for the preparation and use thereof patent thumbnailModified membrane spanning proteins and methods for the preparation and use thereof
In accordance with the present invention, there are provided functionally modulated tool receptors which are useful for drug discovery and development. In certain aspects and embodiments as described herein, a sophisticated and powerful approach has been designed that allows the rapid development of enhanced receptors, while simultaneously exploring millions of possibilities for improved properties with respect to such properties as protein expression, homogeneity, stabilization, conformational and activation pathway selectivity, antigenicity, immunogenicity, and the like.
Abilita Bio, Inc.


05/05/16
20160122439 
 Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof patent thumbnailAnti-dll4/vegf dual variable domain immunoglobulin and uses thereof
Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant dll4 and/or vegf expression or activity.. .
Abbvie Inc.


05/05/16
20160122437 
 Antibodies to matrix metalloproteinase 9 patent thumbnailAntibodies to matrix metalloproteinase 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.


04/28/16
20160115210 
 Colorimetric and fluorescent proteins patent thumbnailColorimetric and fluorescent proteins
The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.. .
Board Of Trustees Of Michigan State University


04/21/16
20160109424 
 Swath™ data-independent acquisition technology for the detection of host cell protein contaminants in biotherapeutics protein products patent thumbnailSwath™ data-independent acquisition technology for the detection of host cell protein contaminants in biotherapeutics protein products
Systems and methods are provided for detecting host cell contaminants in a protein biotherapeutic product using sequential windowed acquisition tandem mass spectrometry. Sequential windowed acquisition is performed on a protein biotherapeutic product sample by sequentially stepping a precursor mass window across a mass range, fragmenting transmitted precursor ions of each stepped precursor mass window, and analyzing product ions produced from the fragmented transmitted precursor ions.

04/21/16
20160106850 
 Methods and compositions for wound treatment patent thumbnailMethods and compositions for wound treatment
The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.. .

04/14/16
20160102150 

Plasma kallikrein binding proteins


Plasma kallikrein binding proteins and methods of using such proteins are described.. .

04/07/16
20160097053 

Yeast promoters from pichia pastoris


In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from pichia pastoris wherein the nucleic acids have promoter activity are described.
Keck Graduate Institute Of Applied Life Sciences


04/07/16
20160097050 

Devices and methods for display of encoded peptides, polypeptides, and proteins on dna


A novel method for displaying proteins and peptides is disclosed in which individual proteins or peptides remain associated with the dna encoding them. Proteins or peptides can be generated by in vitro translation of dna templates, either free in solution or arrayed on a solid support, such that the proteins or peptides remain immobilized on their dna templates.
The Board Of Trustees Of The Leland


04/07/16
20160095917 

Dps fusion proteins for use in vaccines and diagnostics


Novel nanoparticle fusion proteins comprising proteins or peptides fused to dps (dna binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.. .
Kj Biosciences Llc


04/07/16
20160095313 

Antimicrobial compositions and methods


The present invention is generally related to a product and process to reduce the microbial contamination on organic matter, such as processed meat, fruits and vegetables, plant parts, inanimate surfaces such as textiles and stainless steel, and in the mouth or on dental products. In particular, the invention is related to a product and process to disinfect surfaces using an antimicrobial composition containing an antimicrobial lipid, an enhancer selected from the group consisting of bacteriocins, antimicrobial enzymes, sugars, sugar alcohols, iron-binding proteins and derivatives thereof, siderophores, and combinations thereof, and optionally a surfactant..
3m Innovative Properties Company


03/31/16
20160090414 

Binding proteins specific for insulin-like growth factors and uses thereof


Binding proteins, such as antibodies directed to igf-ii with cross-reactivity to igf-i and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the igf-ii with cross-reactivity to igf-i are disclosed.
Medimmune Limited


03/31/16
20160090404 

Modified biotin-binding protein, fusion proteins thereof and applications


The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen.
Children's Medical Center Corporation


03/31/16
20160089445 

Derivatisation of biological molecules


The polymers are particularly suitable for derivatising proteins, such as interferon-α.. .

03/24/16
20160082083 

Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity


Insulin-like growth factor binding proteins (igfbps) and variants thereof, including igfbp-1, igfbp-2, igfbp-3, igfbp-4, igfbp-5, igfbp-8 and the c-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin b activity.. .
National Research Council Of Canada


03/24/16
20160081348 

Decontamination solution and its use for denaturation, modification, degradation, solubilisation and removal of proteins, nucleic acid molecules and microorganisms


The invention concerns a three component system comprising surface-active substances, vitamins and metal ions for efficient destruction and removal of contaminating proteins, nucleic acids and microorganisms from surfaces like for example laboratory benches, floors, equipment and instruments. These non-corrosive and non-toxic solutions for removal of proteins, nucleic acids and microorganisms are applied by spraying, rubbing or immersion of contaminated surfaces thereby destroying, solubilizing inactivating and removing proteins and nucleic acids.
Multibind Biotec Gmbh


03/17/16
20160076052 

Design synthetic genes


The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a gc content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a gc content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes..
Jnc Corporation


03/17/16
20160075773 

Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration


The present application describes rgm a binding proteins, particularly monoclonal antibodies, and in particular cdr grafted, humanized versions thereof, which have the ability to bind to rgm a and prevent binding of rgm proteins to rgm a receptor and other rgm a binding proteins, and therefore neutralize the function of rgm a, for use in the treatment of retinal nerve fiber layer (rnfl) degeneration as well as methods of therapeutically or prophylactically treating a mammal against rnfl degeneration.. .
Abbvie Deutschland Gmbh & Co. Kg


03/17/16
20160075743 

Methods and materials for encapsulating proteins


The invention provides a method for encapsulating a protein of interest, the method comprising the step of expressing a fusion protein comprising an n-terminal region of a rearrangement hot spot (rhs)-repeat-containing protein fused to the protein of interest. The invention further provides applications for the encapsulation, release and delivery of the protein of interest.
Agresearch Ltd


03/17/16
20160074373 

Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs


Compositions and methods concern organic molecules that bind to human atox1 and ccs at the copper trafficking interface of these proteins. This binding suppresses copper trafficking, which leads to inhibition of cancer cell proliferation and tumor growth.
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences


03/10/16
20160069893 

Methods and compositions for analyzing proteins


Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs.
Monogram Biosciences, Inc.


03/10/16
20160068614 

Bonding tissues and cross-linking proteins with naphthalimide compounds


Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together.
Alumend, Llc


03/10/16
20160067674 

Ligands and methods for isolating or removing proteins


The present disclosure relates generally to sorbents for binding proteins from blood plasma comprising a solid carrier material and an oligopeptide immobilized thereon, which selectively binds the protein from the blood plasma, and to a method for separating autologous proteins from blood plasma wherein the blood plasma is brought in contact with a corresponding sorbent, the desired protein is allowed to bind to the sorbent, the sorbent is separated from the plasma and the protein is subsequently separated from the sorbent. Corresponding sorbents and method allows for the selective isolation of specific blood plasma proteins directly from the blood plasma without having to conduct a tedious fractionation.
Previpharma Ag


03/10/16
20160066611 

Process for preparing a pumpable broth composition


Disclosed here is a process for preparing a concentrated liquid composition (such as a broth) from poultry or other meat sources without the use of any enzymes. The resultant composition may have high content of solids but are pumpable or pourable and have relatively long shelf life at room temperature.
International Dehydrated Foods, Inc.


03/03/16
20160063177 

Automated computational enzyme identification and design


The invention provides computational methods for engineering, selecting, and/or identifying proteins with a desired activity. Further provided are automated computational design and screening methods to engineer proteins with desired functional activities including, but not limited to ligand binding, catalytic activity, substrate specificity, regioselectivity and/or stereoselectivity..

03/03/16
20160060662 

Desaturases of a green microalga and uses thereof


Isolated proteins which are at least partially encoded by polynucleotide sequences encoding novel desaturases are provided together with a composition which includes these isolated proteins. A transgenic plant, a transgenic alga, or a transgenic seed transformed by the polynucleotides encoding proteins which are at least partially encoded by novel desaturases are also provided.
Ben Gurion University Of The Negev Research And Development Authority


03/03/16
20160060656 

Methods and compositions for the treatment of lysosomal storage diseases


Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.. .
Sangamo Biosciences, Inc.


03/03/16
20160060640 

Coryneform bacterium and producing heterologous fusion proteins


The present invention provides a coryneform bacterium having an ability to produce a heterologous fusion protein by secretory production, which has been modified to express a genetic construct for secretory production of the heterologous fusion protein encoding at least a heterologous fusion protein comprising an extein and an intein having an activity of acyl rearrangement. The method for producing proteins modified at the c-terminus is also provided..
Ajinomoto Co., Inc.


03/03/16
20160060591 

Feed media


The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods..
Amgen Inc.


03/03/16
20160060359 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


03/03/16
20160060332 

Therapeutic dll4 binding proteins


Improved dll4 binding proteins are described, including antibodies, cdr-grafted antibodies, human antibodies, and dll4 binding fragments thereof, proteins that bind dll4 with high affinity, and dll4 binding proteins that neutralize dll4 activity. The dll4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant dll4 expression or activity such as autoimmune disorders including multiple sclerosis..
Abbvie Inc.


03/03/16
20160060327 

Anti-infective binding proteins that bind aip2


There is disclosed compositions and methods relating to or derived from anti-aip2 antibodies. More specifically, there is disclosed fully human antibodies that bind aip2, aip2-binding fragments and derivatives of such antibodies, and aip2-binding polypeptides comprising such fragments.
Sorrento Tharapeutics, Inc.


03/03/16
20160058863 

Low viscosity concentrated protein dispersions


Disclosed herein are, inter alia, low viscosity dispersions comprising proteins and viscosity lowering agents; pharmaceutical compositions comprising low viscosity dispersions; and methods of making and using the pharmaceutical compositions and low viscosity dispersions.. .
Board Of Regents, The University Of Texas System


03/03/16
20160057979 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


02/25/16
20160054327 

Rapid protein labeling and analysis


The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein.
Life Technologies Corporation


02/25/16
20160053300 

Nanopore biosensors for detection of proteins and nucleic acids


Described herein are nanopore biosensors based on a modified cytolysin protein. The nanopore biosensors accommodate macromolecules including proteins and nucleic acids, and may additionally comprise ligands with selective binding properties..
Katholieke Universiteit Leuven


02/25/16
20160053298 

Methods for identifying proteins and compounds that modulate the activity of otub1


The present invention describes that otub1 cleavage of k48 poly-ubiquitin is stimulated by a select subset of e2 enzymes, and that this stimulation is regulated by the ubiquitin-charged state of the e2 and free ubiquitin. Structural and biochemical studies of otub1 and ubch5b show that the e2 stimulates binding of the polyubiquitin substrate by contacting the otub1 n-terminal ubiquitin-binding helix.
The Johns Hopkins University


02/25/16
20160053014 

Antigen binding proteins that bind cxcr5


There is disclosed compositions and methods relating to or derived from anti-cxcr5 antibodies. More specifically, there is disclosed fully human antibodies that bind cxcr5, cxcr5-binding fragments and derivatives of such antibodies, and cxcr5-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


02/25/16
20160053013 

Antigen binding proteins that bind cxcr3


There is disclosed compositions and methods relating to or derived from anti-cxcr3 antibodies. More specifically, there is disclosed fully human antibodies that bind cxcr3, cxcr3-binding fragments and derivatives of such antibodies, and cxcr3-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


02/25/16
20160053000 

Apelin antigen-binding proteins and uses thereof


This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis.
Amgen Inc.


02/25/16
20160052965 

Dimeric iap inhibitors


Molecular mimics of smac are capable of modulating apoptosis through their interaction with cellular iaps (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the n-terminal tetrapeptide of iap-binding proteins, such as smac/diablo, hid, grim and reaper, which interact with a specific surface groove of iap.
Tetralogic Birinapant Uk Ltd.


02/25/16
20160052963 

Process for purification of a fatty acid binding protein


A process for purification of a fatty acid binding proteins such as, e.g., sm14 of pichia pastoris or type-3 fabp protein of fasciola hepatica. The process includes the steps of: (a) performing lysis of cells containing the fatty acid binding protein to obtain a lysate; (b) clarifying the lysate obtained in step (a) to obtain a clarified lysate; (c) loading the clarified lysate in a column containing an anion exchange resin; (d) eluting proteins from the column by ph changes in the column; and (e) separating contaminant proteins from the fatty acid binding protein by gel-filtration..
Alvos-consultoria, Desenvolvimento E Commercializacao De Produtos Biotecnologicos S/a


02/18/16
20160046730 

Dual variable domain immunoglobulins and uses thereof


Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.. .
Abbvie


02/18/16
20160046727 

Heterodimeric antibody fc-containing proteins and methods for production thereof


Novel heterodimeric antibody-fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins. .
Genmab A/s


02/18/16
20160046726 

Specific binding proteins and uses thereof


The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (egfr) and to the de2-7 egfr truncation of the egfr. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification.
Ludwig Institute For Cancer Research Ltd.


02/18/16
20160046725 

Novel antigen binding proteins and their use as addressing product for the treatment of cancer


The present invention relates to novel antigen binding proteins, in particular monoclonal antibodies, capable of binding to the protein axl as well as the amino and nucleic acid sequences coding for said proteins. From one aspect, the invention relates to novel antigen binding proteins, or antigen binding fragments, capable of binding to axl and, by inducing internalization of axl, being internalized into the cell.
Pierre Fabre Medicament


02/18/16
20160046713 

Anti-kir3d antibodies


The present invention provides antigen-binding proteins capable of binding to kir3d polypeptides. The antibodies have increased activity in the treatment of disorders characterized by kir3dl2-expressing cells, particularly cd4+ t cells, including malignancies such as mycosis fungoides and sézary syndrome..
Innate Pharma


02/18/16
20160046702 

Immunoregulatory structures from normally occuring proteins


The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumour. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified.
Canimguide Therapeutics Ab


02/11/16
20160041180 

Method for evaluating urine sample, analyzer, and analysis system


A method for obtaining information about proteinuria and/or nephropathy from urine samples is provided for evaluating a urine sample that includes detecting proteins in the urine sample with two types of detection reagents that differ in reactivity to at least one urinary protein; and based on an indicator calculated using the results of the detection with the two types of detection reagents.. .
Arkray, Inc.


02/11/16
20160040146 

Purification of recombinant alpha galactosidase a


In one embodiment, the invention provides a method of purifying recombinant alpha-galactosidase a. The method includes obtaining a lysate from cells recombinantly expressing alpha-galactosidase a grown in a cell culture medium having non-precipitating phosphate; contacting said lysate with a first chromatography media that binds α-d-mannopyranosyl or α-d-glucopyranosyl; eluting alpha-galactosidase a from the first chromatography media to generate a first eluate having alpha-galactosidase a, wherein said eluting includes at least one elution pause between 4 and 16 hours; contacting the first eluate with a second chromatography media that binds galactose binding proteins; and eluting alpha-galactosidase a from said second chromatography media to generate a second eluate containing said recombinant alpha-galactosidase a..
Research Foundation Of The City University Of New York


02/11/16
20160039945 

Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9


The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr. In embodiments, the antigen binding proteins specifically bind pcsk9.
Amgen Inc.


02/11/16
20160039940 

Human cd30 ligand antigen binding proteins


Provided are compositions and methods relating to human cd30l antigen binding proteins. Compositions described herein include: human cd30l antigen binding proteins, polynucleotides encoding human cd30l antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions.
Novo Nordisk A/s


02/04/16
20160032014 

Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9


The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting pcsk9 binding to ldlr and having increased ph sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind pcsk9 and have increased ph sensitivity, improved binding affinity and/or increased in vivos half life.
Amgen Inc.


02/04/16
20160032000 

Blood-brain-barrier dual variable domain immunoglobulins and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.


02/04/16
20160031999 

Il-11r binding proteins


The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (il-11) receptor alpha (il-11rα) and uses thereof, e.g., in therapy.. .
45 Poplar Road


02/04/16
20160031997 

Methods and compositions relating to anti-ccr7 antigen binding proteins


The present invention provides compositions and methods relating to antigen binding proteins against ccr7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.. .
Amgen Inc.


02/04/16
20160031986 

Therapeutic dll4 binding proteins


Dll4 binding proteins are described herein, including antibodies, cdr-grafted antibodies, humanized antibodies, and dll4 binding fragments thereof, proteins that bind dll4 with high affinity, and dll4 binding proteins that neutralize dll4 and/or vegf activity. The dll4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis..
Abbvie Inc.


02/04/16
20160031985 

Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use


The disclosure relates to charge-engineered antibodies and penetration-enhanced targeted proteins and their uses for therapeutic treatment or therapeutics delivery.. .
Permeon Biologics, Inc.


02/04/16
20160031832 

Quinazolinone antibiotics


A new class of antibiotics effective against methicillin-resistant staphylococcus aureus (mrsa) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (pbp) 2a.
University Of Notre Dame Du Lac


02/04/16
20160030584 

Method for preserving and stabilising proteins, which can be used for industrial development of formulations of sanitary, pharmaceutical and cosmetic products


A method for preserving and stabilising proteins is disclosed which can be used for the industrial development of formulations of sanitary, pharmaceutical and cosmetic products, particularly cell growth factors and/or proteins such as epidermal growth factor (egf) and fibroblast growth factor (bfgf). The method includes a dispersion phase, under normal pressure and temperature conditions, in which the proteins are incorporated into an anhydrous medium formed by oily components that have hydrophilic residues and that guarantee interactions with the proteins, while maintaining the native conformation of the proteins, such components being grape seed oil, a base of different components and butylhydroxytoluene..
Sani-red, S.l.


01/28/16
20160025747 

Use and treatment of di-amino acid repeat-containing proteins associated with als


Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (als) or frontotemporal dementia (ftd). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein..
University Of Florida Research Foundation, Inc.


01/28/16
20160024558 

Nucleic acid binding proteins and uses thereof


Compositions, systems and methods employing nucleic acid binding proteins for use in the regulation and/or modulation of nucleic acid based reactions, including transcription, translation, modification, digestion, and hybridization reactions. Such compositions are employed in controlling a variety of different reaction types involving nucleic acids..
10x Genomics, Inc.


01/28/16
20160024511 

Yeast promoters for protein expression


Isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are disclosed. More specifically, nucleic acids isolated from pichia pastoris having promoter activity and expression methods, host cells, expression vectors, and dna constructs of using the pichia pastoris promoters to produce different proteins and polypeptides are disclosed..
Biogrammatics, Inc.


01/28/16
20160024222 

Monoclonal antibodies against antithrombin b


This patent document relates to antibodies, antigen-binding antibody fragments (fabs), and other protein scaffolds, directed against human antithrombin β complexed with heparin and/or heparin-like structure (atβh). These atβh binding proteins can block the anti-coagulant activity of atβ to induce coagulation.
Timothy Myles


01/28/16
20160024196 

Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment


Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the sfrp5 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia elevated glucose levels, elevated insulin levels and diabetic nephropathy..
Amgen Inc.


01/28/16
20160024172 

Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof


The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (rap) and compositions thereof, methods of generating such variants and methods of using such receptor-selective rap variant compositions for therapeutic purposes.. .
Raptor Pharmaceuticals Inc.


01/28/16
20160024161 

Novel binding proteins for pcsk9


The present disclosure relates to novel lipocalin muteins which bind to pcsk9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules..
Daiichi Sankyo Co., Ltd.


01/28/16
20160024096 

Methods and compositions for inhibition of bromodomain-containing proteins


The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.. .
Convergene Llc


01/21/16
20160017047 

Cd20-binding immunotoxins for inducing cellular internalization and methods using same


The present invention provides cd20-binding proteins that bind to and rapidly internalize cd20 antigens from a cell surface location to the interior of a cell. Cd20-binding proteins of the invention comprise a cd20 binding region and a shiga toxin effector region.
Molecular Templates, Inc.


01/21/16
20160017037 

Anti-lag-3 binding proteins


Antigen binding proteins that bind lymphocyte activation gene 3 (lag-3), and more particularly to antigen binding proteins that cause depletion of lag-3+ activated t cells.. .
Glaxosmithkline Intellectual Property Development Limited


01/21/16
20160015555 

Tissue crosslinking for treatment of snoring and obstructive sleep apnea


A method of treating snoring and/or osa in a subject in need of such treatment. The method includes crosslinking proteins of the subject's soft palate tissue or pharynx tissue.
Orthopeutcs. L.p.


01/07/16
20160004812 

Pharmacogenic therapies targeting the metal-ion transcriptional regulation machinery in bacteria


The subject invention pertains to methods of identifying compounds that bind to a binding pocket on metal ion binding proteins of arsr/smtb family and modulate their regulatory activity by increasing the propensity of the protein to remain in a conformationally trapped form such as the metal ion bound conformation or disulfide-linked conformation, dna bound conformation, or the apo-conformation. The invention provides methods of identifying such compounds using computer software programs.
University Of Florida Research Foundation, Incorporated


01/07/16
20160002625 

Cancer treatment


In certain embodiments, methods, compounds, and compositions for treating b-cell lymphoma or hepatocellular carcinoma by inhibiting expression of st at3 mrna or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate b-cell lymphoma or hepatocellular carcinoma.
Isis Pharmaceuticals Inc.


01/07/16
20160002623 

Genes expressed in mental illness and mood disorders


The present invention relates to a composition comprising a plurality of cdna molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar i disorder, bipolar ii disorder, unipolar disorder, schizophrenia, attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cdna molecules may be used in their entirety or in part as to diagnose, to stage, to treat, and/or to monitor the treatment of a subject with mental illness..
Psychnostics, Llc


01/07/16
20160002346 

Her1 antigen binding proteins binding to the beta-hairpin of her1


The invention relates to anti-her1 antigen binding proteins, e.g. Anti-her1 antibodies, that bind to the beta-hairpin of her1, methods for selecting these antigen binding proteins, their preparation and use as medicament..
Hoffmann-la Roche Inc.


01/07/16
20160002343 

Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases


Engineered agents or multivalent and multispecific binding proteins capable of penetrating the cells or tissue of the blood-brain barrier (bbb) are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.


01/07/16
20160002333 

Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


01/07/16
20160002326 

Compositions and methods for treating rheumatoid arthritis


The treatment of rheumatoid arthritis using engineered multivalent and multispecific binding proteins that target tnf and il-17 is provided.. .
Abbvie Inc.


01/07/16
20160002324 

Anti-ngf antibodies and their use


The present disclosure encompasses ngf binding proteins, specifically to antibodies that are chimeric, cdr grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting ngf and for inhibiting ngf activity, e.g., in a mammal subject suffering from a disorder in which ngf activity is detrimental..
Zoetis Belgium S.a.


01/07/16
20160002121 

Methods and compositions for radiohalogen protein labeling


Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests.
Genentech, Inc.


12/31/15
20150376286 

Human cgrp receptor binding proteins


Antigen binding proteins that bind to human cgrp receptor (cgrp r) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided.
Amgen Inc.


12/31/15
20150376246 

High affinity digoxigenin binding proteins


Isolated polypeptides with steroid binding activity and methods for their use as therapeutics and detection agents are disclosed herein.. .
University Of Washington Through Its Center For Commercialization


12/31/15
20150376229 

Tangential flow filtration based protein refolding methods


Provided herein are methods for refolding proteins that are denatured. Exemplary methods comprise solubilizing the denatured protein with a denaturing agent, e.g., a chaotropic agent, and renaturing the protein using a buffer exchanging system, e.g., tangential flow filtration (tff)..
Bristol-myers Squibb Company


12/31/15
20150374837 

Antibacterial agent for treating infectious diseases of bacterial origin


The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant tb which represents the ion nanostructured complex (insc) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as phe, ala, val, ala, leu, ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant tb; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (bafs or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. Insc has the formula [{(ln(mei3)+)y[me(lm)i]+x}(cl—)y+x+k] with m=30-300 kda..
"scientific Center Of Anti-infectious Drugs" Joint-stock Company


12/24/15
20150369711 

Fluorous affinity extraction for ionic liquid-based sample preparation


A method for removing an ionic liquid from an aqueous sample is provided. In some embodiments, the method includes: (a) combining an aqueous sample including an ionic liquid with an ion exchanger composition including an ion exchanger counterion to produce a solution including a fluorous salt of the ionic liquid, where at least one of the ionic liquid and the ion exchanger counterion is fluorinated; (b) contacting the solution with a fluorous affinity material, thereby removing fluorous salt from the solution and producing an aqueous eluate; and (c) collecting the aqueous eluate.
Agilent Technologies, Inc.


12/24/15
20150368333 

Tnf-alpha antigen-binding proteins


The present invention provides antigen binding proteins which bind specifically to tnf-alpha. For example novel variants of anti-tnf antibodies such as adalimumab which show increased binding to the fcrn receptor or increased half life compared to adalimumab.
Glaxosmithkline Intellectual Property Development Limited


12/24/15
20150368302 

Designed ankyrin repeat proteins binding to platelet-derived growth factor


New designed ankyrin repeat proteins with binding specificity for pdgf-bb are described, as well as nucleic acids encoding such pdgf binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.. .
Molecular Partners Ag


12/24/15
20150368299 

Amyloid-beta binding proteins


The present invention relates to amyloid-beta (aβ) binding proteins. Antibodies of the invention have high affinity to aβ(20-42) globulomer or any β form that comprises the globulomer epitope.
Abbvie Inc.


12/17/15
20150361420 

Methods for screening proteins using dna encoded chemical libraries as templates for enzyme catalysis


Disclosed are methods, compositions and devices for screening a protein library for proteins having a desired activity, such as capable of catalyzing the formation of a bond between two reactants. In an exemplary embodiments, a plurality of proteins are expressed in vitro from a plurality of nucleic acids, the plurality of proteins are exposed with two single stranded oligonucleotides having complementary sequences, each oligonucleotide having a reactant and a fluorophore, the fluorescence of the protein-reactant-oligonucleotide-fluorophore complexes is detected and the complexes showing detectable fluorescence energy transfer are isolated, thereby isolating proteins having the desired enzymatic activity..
Gen9, Inc.


12/17/15
20150361130 

Capture purification processes for proteins expressed in a non-mammalian system


Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed.
Amgen Inc.




G Proteins topics: G Proteins, Antibodies, Immunoglobulin, Metalloprotein, Chemotherapeutic Agent, Kinase Inhibitor, Tetrapeptide, Apoptosis Protein, Topoisomerase, Peptidomimetic, Fractionation, Medical Treatment, Chromatograph, Encapsulation, Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to G Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3596

4675

2 - 1 - 101